Sign In
Buy INZY
$4.00
+0 (+0%)
At Close: Sep 30, 2025
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
08:30am, Wednesday, 27'th Nov 2024
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for ra
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks
10:36am, Wednesday, 13'th Nov 2024
Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings esti
Inozyme Pharma to Present at Upcoming Investor Conferences
08:30am, Monday, 11'th Nov 2024
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for ra
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
08:30am, Tuesday, 05'th Nov 2024
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 –
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701
01:15pm, Thursday, 24'th Oct 2024
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for r
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
08:30am, Monday, 07'th Oct 2024
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for r
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
02:35pm, Thursday, 12'th Sep 2024
Stifel initiated coverage on Inozyme Pharma Inc. INZY, saying, “This under-the-radar stock could be worth a look ahead of it.”
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
08:30am, Thursday, 29'th Aug 2024
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for ra
Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
01:56pm, Tuesday, 30'th Jul 2024
Inozyme Pharma, Inc. interim data from the phase 1 SEAPORT-1 study, using INZ-701 for the treatment of patients with end-stage kidney disease with hemodialysis with calciphylaxis, expected Q4 of 2024.
- Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT -
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
08:30am, Tuesday, 02'nd Jul 2024
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency Agency program will support and expedite clinical studies addressing severe unm
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented Results from a radiographic study describing skeletal features of pediatric
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeuti
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
08:30am, Wednesday, 08'th May 2024
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics
